SciClone's Quarter Sales Growth Marred By FCPA Investigation Of China Operations
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - U.S. regulatory authorities have launched an investigation into the China operations of Hong Kong-based and Nasdaq-listed SciClone Pharmaceuticals, a specialty pharmaceutical company
You may also be interested in...
Could Less Enforcement Action Of Foreign Corrupt Practices Act Mean Compliance Is Improving?
HONG KONG - Enforcement of anti-corruption legislation remains strong but nowhere near the publicly aggressive levels of 2010. This year is on track to beat 2009 and maintain the upward trend in the number of actions and the size of the fines levied by authorities in the United States under the Foreign Corrupt Practices Act, according to Arnold & Porter, a U.S. law firm
Could Less Enforcement Action Of Foreign Corrupt Practices Act Mean Compliance Is Improving?
HONG KONG - Enforcement of anti-corruption legislation remains strong but nowhere near the publicly aggressive levels of 2010. This year is on track to beat 2009 and maintain the upward trend in the number of actions and the size of the fines levied by authorities in the United States under the Foreign Corrupt Practices Act, according to Arnold & Porter, a U.S. law firm
A Long Way Still For Corrupt Business Practices In China, India - Pharmaceutical Regulatory And Compliance Congress
SINGAPORE - Major Chinese pharma companies are eyeing acquisitions of companies in lucrative Western markets to establish a global foothold, according to industry observers